Seller record · Telehealth service

Human+

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 4 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The page refers only to a network of licensed US compounding pharmacies. 3 more criteria also fail; see the table below.

At a glance

Human+Telehealth service

4/8criteria passed

Price: Not printed before a consultation or sign-up
Sells: compounded semaglutide injection, compounded tirzepatide injection, and 2 more
FDA letters: None on file

Visit Human+See all eight dispositions

Telehealth service. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A telehealth service built around fatty liver disease whose licensed providers prescribe compounded semaglutide and tirzepatide, as injections or oral forms, after an online medical intake; its public page promises flat pricing without printing an amount.

Operating entity Human+ Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Human+'s website
S2	Prescription gating	PASS	Human+'s website
S3	Pharmacy identification	FAIL	Human+'s website
S4	Compounding disclosure	PASS	Human+'s website
S5	Analytical documentation	FAIL	Human+'s website
S6	Business address	FAIL	Human+'s website
S7	Price disclosure	FAIL	Human+'s website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA US-licensed provider reviews each intake and labs, and the safety information says the company's clinicians decide whether to prescribe compounded GLP-1s after meeting the patient.Source: Human+'s website.

S2PASSThe steps list a short medical questionnaire first, and the safety information says the answers screen out patients who do not qualify before checkout, with a clinician meeting the patient after it.Source: Human+'s website.

S3FAILNo filling pharmacy is named. The page refers only to a network of licensed US compounding pharmacies.Source: Human+'s website.

S4PASSThe footer states that compounded medications are not FDA-approved and are not evaluated by the FDA, and the page describes the semaglutide and tirzepatide as compounded.Source: Human+'s website.

S5FAILNo certificate of analysis or lot document is published, and the site has no page beyond its home page.Source: Human+'s website.

S6FAILNo postal address is printed. The footer names Human+ Health, Inc. with the cities San Francisco and New York only, and the site has no contact, terms or privacy page.Source: Human+'s website.

S7FAILNo price is printed. The page promises one flat price with shipping included and no membership fee, and its pricing link leads nowhere.Source: Human+'s website.

S8PASSNo FDA warning letter names Human+ or Human+ Health, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injection, compounded tirzepatide injection, oral semaglutide, oral tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Human+

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.